Tang Capital Management LLC holds a focused book of 51 stocks worth $2.0B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Compass Pathways PLC and trimmed Lakefront Biotherapeutic-ADR. Their largest long position is Aurinia Pharmaceuticals Inc at 9% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1232621/holdings"
Use Arkolith to show TANG CAPITAL MANAGEMENT LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
94% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Aurinia Pharmaceuticals Inc COM | $181.2M | 12.23M | 9.2% | ▲+7.9% Added · +900K sh | |
| 2 | Celcuity Inc COM | $119.8M | 1.05M | 6.1% | —Held | |
| 3 | Mirum Pharmaceuticals Inc COM | $114.2M | 1.24M | 5.8% | —Held | |
| 4 | Galapagos NV SPON ADR | $113.6M | 3.79M | 5.8% | ▼−3.4% Reduced · −135K sh | |
| 5 | State STR SPDR S&P 500 ETF T TR UNIT | $109.3M | 168.0K | 5.5% | ▲+460% Added · +138K sh | |
| 6 | Kiniksa Pharmaceuticals Intl ORD SHS CL A | $108.8M | 2.26M | 5.5% | —Held | |
| 7 | Capricor Therapeutics Inc COM NEW | $103.4M | 3.40M | 5.2% | ▲+100% Added · +1.7M sh | |
| 8 | PTC Therapeutics Inc COM | $102.2M | 1.50M | 5.2% | —Held | |
| 9 | Spyre Therapeutics Inc COM NEW | $95.4M | 1.89M | 4.8% | —Held | |
| 10 | Kalvista Pharmaceuticals Inc COM | $92.1M | 4.57M | 4.7% | —Held | |
| 11 | Compass Therapeutics Inc COM | $88.8M | 16.79M | 4.5% | —Held | |
| 12 | Tarsus Pharmaceuticals Inc COM | $83.4M | 1.19M | 4.2% | —Held | |
| 13 | Immunocore Hldgs PLC ADS | $79.9M | 2.65M | 4.1% | ▲+0.8% Added · +21K sh | |
| 14 | Anaptysbio Inc COM | $73.8M | 1.33M | 3.7% | ▼−0.1% Reduced · −1K sh | |
| 15 | Corcept Therapeutics Inc COM | $60.5M | 1.50M | 3.1% | ▲+857% Added · +1.3M sh | |
| 16 | Ani Pharmaceuticals Inc COM | $54.4M | 707.5K | 2.8% | ▲+47% Added · +226K sh | |
| 17 | Insmed Inc COM PAR $.01 | $42.5M | 260.0K | 2.2% | ▲+333% Added · +200K sh | |
| 18 | Biontech SE SPONSORED ADS | $41.8M | 470.0K | 2.1% | —Held | |
| 19 | Viridian Therapeutics Inc COM | $35.1M | 1.79M | 1.8% | —Held | |
| 20 | Atea Pharmaceuticals Inc COM | $25.9M | 4.81M | 1.3% | —Held | |
| 21 | Precigen Inc COM | $24.8M | 6.42M | 1.3% | ▲+14% Added · +800K sh | |
| 22 | Dianthus Therapeutics Inc COM | $22.2M | 264.7K | 1.1% | —Held | |
| 23 | Compass Pathways PLC SPONSORED ADS | $22.1M | 4.00M | 1.1% | ▲New New position | |
| 24 | Crescent Biopharma Inc. COM | $21.3M | 1.16M | 1.1% | ▲+33% Added · +288K sh | |
| 25 | Stoke Therapeutics Inc COM | $16.3M | 500.0K | 0.8% | —Held | |
| 26 | Viking Therapeutics Inc COM | $16.3M | 500.0K | 0.8% | —Held | |
| 27 | Ideaya Biosciences Inc COM | $15.0M | 450.0K | 0.8% | —Held | |
| 28 | Nuvation Bio Inc COM CL A | $13.5M | 3.15M | 0.7% | ▼−18% Reduced · −708K sh | |
| 29 | Pliant Therapeutics Inc COM | $7.7M | 6.14M | 0.4% | —Held | |
| 30 | Journey Med Corp COM | $7.6M | 1.61M | 0.4% | ▼−13% Reduced · −245K sh | |
| 31 | Janux Therapeutics Inc COM | $7.0M | 500.0K | 0.4% | ▲New New position | |
| 32 | Biogen Inc COM | $6.4M | 35.0K | 0.3% | —Held | |
| 33 | Urogen Pharma Ltd COM | $6.3M | 350.0K | 0.3% | —Held | |
| 34 | Arvinas Inc COM | $5.7M | 538.7K | 0.3% | ▼−5.4% Reduced · −31K sh | |
| 35 | PMV Pharmaceuticals Inc COM | $5.3M | 4.25M | 0.3% | ▼−14% Reduced · −695K sh | |
| 36 | Moderna Inc COM | $5.1M | 100.0K | 0.3% | ▼−86% Reduced · −593K sh | |
| 37 | Heron Therapeutics Inc COM | $5.0M | 6.25M | 0.3% | —Held | |
| 38 | Kezar Life Sciences Inc COM NEW | $4.9M | 664.3K | 0.3% | —Held | |
| 39 | Wave Life Sciences Ltd SHS | $4.3M | 600.0K | 0.2% | —Held | |
| 40 | Lenz Therapeutics Inc COM | $4.1M | 451.1K | 0.2% | ▼−48% Reduced · −414K sh | |
| 41 | Agios Pharmaceuticals Inc COM | $3.4M | 100.0K | 0.2% | ▲New New position | |
| 42 | Erasca Inc COM | $3.2M | 200.0K | 0.2% | ▼−78% Reduced · −700K sh | |
| 43 | Coherus Oncology Inc COM | $3.2M | 1.89M | 0.2% | ▼−31% Reduced · −838K sh | |
| 44 | Nkarta Inc COM | $3.1M | 1.48M | 0.2% | —Held | |
| 45 | Altimmune Inc COM NEW | $2.1M | 666.0K | 0.1% | ▼−69% Reduced · −1.5M sh | |
| 46 | Evolus Inc COM | $2.0M | 483.0K | 0.1% | ▼−61% Reduced · −763K sh | |
| 47 | Abeona Therapeutics Inc COM NEW | $1.8M | 400.0K | 0.1% | ▼−60% Reduced · −600K sh | |
| 48 | Fate Therapeutics Inc COM | $1.4M | 1.17M | 0.1% | —Held | |
| 49 | Neumora Therapeutics Inc. COM | $858K | 439.9K | 0.0% | ▼−55% Reduced · −527K sh | |
| 50 | Lexicon Pharmaceuticals Inc COM NEW | $624K | 399.7K | 0.0% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 51 | $2.0B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 75 | $2.0B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 194 | $2.6B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 200 | $2.0B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 202 | $1.8B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 183 | $1.5B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 154 | $1.4B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 128 | $981.9M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 99 | $960.4M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 123 | $1.1B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 106 | $708.7M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 99 | $679.3M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 103 | $671.1M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 89 | $688.3M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 95 | $815.4M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 67 | $659.0M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 53 | $499.9M | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 29 | $497.2M | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 20 | $481.7M | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 16 | $502.4M | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 11 | $355.4M | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 11 | $655.0M | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 16, 2020 | 20 | $552.7M | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 14, 2020 | 21 | $1.0B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.